Do IFIH1 rs1990760 and CTLA4 rs231775 variants increase risk of autoimmune thyroid disease?

Genetic research provides strong support for the association between specific variants in the CTLA4 and IFIH1 genes and an increased risk of autoimmune diseases, particularly autoimmune thyroid disease (AITD). These variants represent distinct but converging pathways of immune dysregulation involving both the innate and adaptive immune systems.

Clinical and genetic evidence

The evidence for these genetic markers is robust, though the strength of association varies by gene and specific condition:

• CTLA4 rs231775 (+49A/G): This is one of the most consistently replicated genetic risk factors for AITD, including Graves' disease and Hashimoto's thyroiditis. The G allele is linked to significantly higher susceptibility, with meta-analyses showing odds ratios (OR) between 1.42 and 1.50 in certain populations.
• IFIH1 rs1990760 (A946T): This variant is a well-established risk factor for a spectrum of autoimmune conditions, including Type 1 Diabetes (T1D), systemic lupus erythematosus (SLE), and Graves' disease. While its link to AITD is considered plausible and supported by several meta-analyses, some individual studies show more modest effects (OR ~1.09) or inconsistent results across different ethnic groups and age cohorts.

Mechanistic explanations

The biological impact of these variants explains how they lower the threshold for autoimmunity:

• Adaptive immune checkpoint (CTLA4): The CTLA4 rs231775 variant disrupts the leader peptide of the CTLA-4 protein, impairing its trafficking to the cell surface. This reduction in surface expression on regulatory T cells (Tregs) and activated T cells diminishes the "braking" signal necessary to suppress autoreactive T cells. Without adequate CTLA-4 inhibition, effector T cells are more easily activated against thyroid antigens like TPO and the TSH receptor.
• Innate immune sensing (IFIH1): The IFIH1 rs1990760 variant affects MDA5, a sensor that detects viral RNA. This specific mutation is a "gain-of-function" variant that increases basal and stimulated production of Type I interferons (IFN-β). Chronic elevation of interferon signaling creates a pro-inflammatory environment that facilitates the breakdown of self-tolerance.

Clinical implications

For a 59-year-old female, these genetic markers suggest a heightened predisposition to thyroid-related autoimmunity and other co-occurring autoimmune conditions.

• Shared architecture: These variants exhibit "genetic pleiotropy," meaning they increase the risk for multiple diseases simultaneously (e.g., a patient with AITD may also be at higher risk for T1D or vitiligo due to these shared pathways).
• Monitoring: While genetics provide a susceptibility profile, clinical manifestations depend on environmental triggers. The presence of these variants supports vigilant monitoring of thyroid function and autoantibody levels (TPOAb, TgAb, TRAb) if symptoms arise.

Bottom line

The CTLA4 rs231775 variant is a strongly supported risk factor for autoimmune thyroid disease, while the IFIH1 rs1990760 variant is a plausible contributor to a broader "autoimmune-prone" genetic profile. Together, they reflect a failure in both T-cell regulation and innate inflammatory control.